Comparison

Canvas Dx vs BlinkLab Research

Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.

Head to head
About

Canvas Dx

This medical device aids physicians in diagnosing autism spectrum disorder in young children. It uses AI to analyze parent questionnaires, video reviews, and physician assessments to provide a diagnostic output.

Highlights
  • FDA-authorized Software as a Medical Device
  • AI-driven diagnostic analysis
  • Parent/caregiver questionnaire
  • Video analysis by professionals
  • Healthcare provider portal
  • Prescription use only
Read full description

Canvas Dx is for prescription use only. To find a prescriber go to cognoa.com or email support@cognoa.com. Canvas Dx is the first and only FDA-authorized Software as a Medical Device (SaMD) that aids physicians in diagnosing autism spectrum disorder (ASD) in young children. Canvas Dx harnesses clinically validated artificial intelligence (AI) technology to aid physicians in diagnosing ASD in children between the ages 18-72 months who are at risk of developmental delay. Canvas Dx incorporates 3 separate, user-friendly inputs: 1. A parent/caregiver questionnaire that asks about the child’s behavior and development collected via a parent/caregiver-facing app 2. A questionnaire completed by video analysts who review two videos of the child recorded by the parents/caregivers 3. An HCP questionnaire completed by a physician who meets with the child and a parent/caregiver, collected via a healthcare provider portal The Canvas Dx algorithm evaluates all 3 inputs, generating a device output for the prescribing physician to utilize in combination with their clinical judgment. Canvas Dx is not intended for use as a stand-alone diagnostic device but as an adjunct to the diagnostic process. CONTACT: Email: support@cognoa.com Indications for Use Canvas Dx is intended for use by healthcare providers as an aid in the diagnosis of autism spectrum disorder (ASD) for patients ages 18 months through 72 months who are at risk for developmental delay based on concerns of a parent, caregiver, or healthcare provider. The device is not intended for use as a stand-alone diagnostic device but as an adjunct to the diagnostic process. The device is for prescription use only (Rx only). Contraindications There are no contraindications to using Canvas Dx. Precautions, Warnings The Device is intended for use by healthcare professionals trained and qualified to interpret the results of a behavioral assessment examination and to diagnose ASD. The Device is intended for use in conjunction with patient history, clinical observations, and other clinical evidence the HCP determines are necessary before making clinical decisions. For instance, additional standardized testing may be sought to confirm the Device output, especially when the Device result is not Positive or Negative for ASD. Canvas Dx is intended for patients with caregivers who have functional English capability (8th grade reading level or above) and have access to a compatible smartphone with an internet connection in the home environment. The Device may give unreliable results if used in patients with other conditions that would have excluded them from the clinical study. Among those conditions are the following: • Suspected auditory or visual hallucinations or with prior diagnosis of childhood onset schizophrenia • Known deafness or blindness • Known physical impairment affecting their ability to use their hands • Major dysmorphic features or prenatal exposure to teratogens such as fetal alcohol syndrome • History or diagnosis of genetic conditions (such as Rett syndrome or Fragile X) • Microcephaly • History or prior diagnosis of epilepsy or seizures • History of or suspected neglect • History of brain defect injury or insult requiring interventions such as surgery or chronic medication The Device evaluation should be completed within 60 days of the time it is prescribed because neurodevelopmental milestones change rapidly in the indicated age group.

About

BlinkLab Research

This app serves as a tool for evaluating therapies and diagnosing neuropsychiatric disorders like autism. It's also used in research to study brain mechanisms and as a digital biomarker for clinical studies. Additionally, it functions as an educational resource for understanding brain activity.

Highlights
  • Therapy evaluation
  • Diagnostic tool for neuropsychiatric disorders
  • Neuroscience and psychology research
  • Digital biomarker for clinical studies
  • Educational tool for brain functioning
Features
Read full description

BlinkLab Uses: -Therapy evaluation for neurodevelopmental disorders -Diagnostic tool for neuropsychiatric disorders, such as autism and schizophrenia -Research device that can be used in the fields of neuroscience and psychology, to study mechanisms underlying learning and memory formation -A digital biomarker to optimize clinical outcome assessments in clinical studies -Educational tool for any individual who is interested in his/her own brain functioning Indications for Use BlinkLab is not intended for use as a stand-alone diagnostic device, rather it is meant to be used in addition to standard diagnostic practices. BlinkLab is intended to be used by healthcare providers to diagnose autism spectrum disorder (ASD) in infants and young children whose parents, caregivers, or healthcare providers are concerned they may be experiencing developmental delays.

Screenshots

Canvas Dx4 screens
BlinkLab Research3 screens

Verdict

The call

The clearest difference is rating: BlinkLab Research at 5.0 against Canvas Dx's 4.5. BlinkLab Research also leads on update cadence (fortnightly vs every 3 months) and monetization model (free vs ad-supported). Canvas Dx's advantage is iOS requirement (16.1 vs 18.0). On price, ratings volume, ads and in-app purchases there is nothing between them.

Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS

CostPrice · In-app purchases · Ads · Monetization

Both are free to download. Neither carries in-app purchases, so what you see is what you pay.

ReceptionRating · Positive reviews · Number of ratings

BlinkLab Research holds the better App Store score, 5.0 against 4.5. Both are backed by a comparable volume of ratings — 8 and 6 respectively.

UpkeepUpdate frequency

Canvas Dx ships an update every 3 months, BlinkLab Research fortnightly. Both last shipped on October 24, 2026.

Scorecard4 real differences · 6 level
Canvas Dx versus BlinkLab Research: the parameters behind the verdict, then further details
ParameterCanvas DxBlinkLab Research
PriceFreeFree
Rating4.5 (8 ratings)5.0 (6 ratings) — better
Positive reviews—66.7% of reviews
Number of ratings8 — better6
Update frequencyEvery 3 monthsFortnightly — better
AdsNoNo
In-app purchasesNoNo
MonetizationAd-supportedFree — better
DevicesiPhoneiPhone
Requires iOS16.1 — better18.0
Further details — not scored
Size27 MB62 MB
Age rating17+4+
DeveloperCognoa, Inc.BLINKLAB LIMITED

Customer experience

Canvas Dx

All ratings8 ratings
Positive87.5%
Neutral0.0%
Negative12.5%

BlinkLab Research

All ratings6 ratings
Positive100.0%
Neutral0.0%
Negative0.0%
Written reviews3 reviews
Positive66.7%
Neutral0.0%
Negative33.3%

In-app purchases

None

Canvas Dx

No in-app purchases

None

BlinkLab Research

No in-app purchases

Questions

Is Canvas Dx free?
Canvas Dx is free to download, with no in-app purchases.
Is BlinkLab Research free?
BlinkLab Research is free to download, with no in-app purchases.
Which has better reviews, Canvas Dx or BlinkLab Research?
BlinkLab Research is rated higher. Canvas Dx averages 4.5 out of 5 from 8 ratings, while BlinkLab Research averages 5.0 from 6 ratings.
Do Canvas Dx or BlinkLab Research have ads?
Neither Canvas Dx nor BlinkLab Research shows ads.
Which is updated more often, Canvas Dx or BlinkLab Research?
Canvas Dx ships an update every 3 months, and BlinkLab Research fortnightly. Most recently, Canvas Dx was updated on October 24, 2026 and BlinkLab Research on October 24, 2026.

Other comparisons